Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELAV-like RNA binding protein 1 (HuR) is a ubiquitously expressed RNA-binding protein with three RNA recognition motifs, belonging to the ELAV family of proteins. HuR is mainly localized in the nucleus but shuttles to the cytoplasm during cellular activation or stress. By binding AU-rich elements in the 3'-UTR of target mRNAs, HuR stabilizes and/or promotes translation of transcripts involved in cell cycle regulation, proliferation, apoptosis, inflammatory response, adipogenesis, and stress signaling. HuR’s dysregulation is associated with cancer progression (by stabilizing oncogenic mRNAs), metabolic diseases, and inflammation. It is considered a promising RNA-targeted therapeutic intervention point, but its essential roles in normal tissue viability pose notable safety concerns for systemic inhibition.
Drugs and chemical probes typically act by interfering with HuR’s RNA binding domain, modulating its cytoplasmic localization, or reducing mRNA stabilization activity
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ELAV-like RNA binding protein 1 (HuR).